RedHill Biopharma Ltd.
RDHL
$1.02
-$0.01-0.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 50.01% | 65.02% | 69.14% | 68.46% | -- |
| Total Depreciation and Amortization | -72.86% | -62.76% | -55.16% | 100.85% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 87.18% | -96.31% | -94.43% | -100.93% | -- |
| Change in Net Operating Assets | -130.30% | 67.27% | 91.37% | 104.56% | -- |
| Cash from Operations | 43.87% | -380.78% | -48.41% | 34.40% | -- |
| Capital Expenditure | 55.56% | -14.29% | -140.00% | 8.70% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 55.56% | -1,700.00% | -220.00% | -400.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 70.28% | 63.33% | 58.90% | 51.80% | -- |
| Issuance of Common Stock | -58.27% | -72.84% | -79.87% | -54.94% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 96.75% | -54.78% | -88.23% | -- |
| Cash from Financing | -58.97% | -64.84% | -80.24% | -55.95% | -- |
| Foreign Exchange rate Adjustments | 0.00% | 306.25% | 196.00% | 512.50% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -76.51% | -128.77% | -138.83% | -7,875.71% | -- |